Several ALK inhibitors can effectively suppress the oncogenic activity of ALK rearrangement and provide a better outcome; hence, they have emerged as important front-line therapies in advanced ALK-positive lung cancer patients4–8. This evidence concerns the gene ALK and lung cancer.